FibroBiologics Presenting at the ThymUS 2025 Meeting
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company with 240+ patents, announced its participation at the ThymUS 2025 Meeting in Hawaii. Research scientist Simon Gebremeskel will present findings on artificial thymus organoid development for generating functional T cells.
The company's Chief Scientific Officer, Dr. Hamid Khoja, highlighted the potential of artificial thymus organoids to restore thymus functionality, which serves as the T-cell teaching center of the immune system. The research demonstrates promising applications of organoids in treating chronic diseases, leveraging fibroblasts' unique immunomodulatory properties.
Key Company Highlights:
- Houston-based clinical-stage biotechnology firm
- Focuses on fibroblast cells and fibroblast-derived materials
- Developing treatments for multiple conditions including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, and cancer
- Holds extensive patent portfolio across various clinical pathways
FibroBiologics (Nasdaq: FBLG), una società biotecnologica in fase clinica con oltre 240 brevetti, ha annunciato la sua partecipazione al ThymUS 2025 Meeting alle Hawaii. Il ricercatore Simon Gebremeskel presenterà i risultati sullo sviluppo di organoidi di timo artificiale per la generazione di cellule T funzionali.
Il Chief Scientific Officer dell'azienda, il dott. Hamid Khoja, ha sottolineato il potenziale degli organoidi di timo artificiale nel ripristinare la funzionalità del timo, che funge da centro di formazione delle cellule T nel sistema immunitario. La ricerca evidenzia applicazioni promettenti degli organoidi nel trattamento di malattie croniche, sfruttando le proprietà immunomodulatorie uniche dei fibroblasti.
Punti chiave dell’azienda:
- Azienda biotecnologica clinica con sede a Houston
- Specializzata in cellule fibroblastiche e materiali derivati da fibroblasti
- Sviluppa terapie per diverse condizioni tra cui guarigione delle ferite, sclerosi multipla, degenerazione del disco, psoriasi, ortopedia e cancro
- Possiede un ampio portafoglio di brevetti in vari ambiti clinici
FibroBiologics (Nasdaq: FBLG), una empresa biotecnológica en etapa clínica con más de 240 patentes, anunció su participación en el ThymUS 2025 Meeting en Hawái. El científico investigador Simon Gebremeskel presentará hallazgos sobre el desarrollo de organoides de timo artificial para generar células T funcionales.
El director científico de la empresa, el Dr. Hamid Khoja, destacó el potencial de los organoides de timo artificial para restaurar la funcionalidad del timo, que actúa como el centro de enseñanza de las células T en el sistema inmunológico. La investigación demuestra aplicaciones prometedoras de los organoides en el tratamiento de enfermedades crónicas, aprovechando las propiedades inmunomoduladoras únicas de los fibroblastos.
Puntos clave de la empresa:
- Empresa biotecnológica en etapa clínica con sede en Houston
- Enfocada en células de fibroblastos y materiales derivados de fibroblastos
- Desarrolla tratamientos para múltiples condiciones, incluyendo cicatrización de heridas, esclerosis múltiple, degeneración de discos, psoriasis, ortopedia y cáncer
- Posee un amplio portafolio de patentes en diversas vías clínicas
FibroBiologics (나스닥: FBLG)는 240개 이상의 특허를 보유한 임상 단계의 바이오테크 기업으로, 하와이에서 열리는 ThymUS 2025 미팅에 참가한다고 발표했습니다. 연구 과학자 사이먼 게브레메스켈은 기능성 T 세포 생성을 위한 인공 흉선 오가노이드 개발에 관한 연구 결과를 발표할 예정입니다.
회사의 최고 과학 책임자인 하미드 코자 박사는 인공 흉선 오가노이드가 면역 체계의 T 세포 교육 센터인 흉선 기능을 회복시킬 잠재력을 강조했습니다. 이 연구는 섬유아세포의 독특한 면역조절 특성을 활용하여 만성 질환 치료에 오가노이드가 유망하게 적용될 수 있음을 보여줍니다.
회사 주요 내용:
- 휴스턴에 기반을 둔 임상 단계 바이오테크 기업
- 섬유아세포 및 섬유아세포 유래 소재에 집중
- 상처 치유, 다발성 경화증, 디스크 퇴행, 건선, 정형외과, 암 등 다양한 질환 치료제 개발 중
- 다양한 임상 경로에 걸친 광범위한 특허 포트폴리오 보유
FibroBiologics (Nasdaq : FBLG), une entreprise biotechnologique en phase clinique détenant plus de 240 brevets, a annoncé sa participation au ThymUS 2025 Meeting à Hawaï. Le chercheur Simon Gebremeskel présentera ses travaux sur le développement d'organoïdes thymiques artificiels pour la production de cellules T fonctionnelles.
Le directeur scientifique de l'entreprise, le Dr Hamid Khoja, a souligné le potentiel des organoïdes thymiques artificiels pour restaurer la fonctionnalité du thymus, qui constitue le centre d'apprentissage des cellules T du système immunitaire. Cette recherche met en évidence des applications prometteuses des organoïdes dans le traitement des maladies chroniques, en tirant parti des propriétés immunomodulatrices uniques des fibroblastes.
Points clés de l’entreprise :
- Entreprise biotechnologique en phase clinique basée à Houston
- Se concentre sur les cellules fibroblastes et les matériaux dérivés des fibroblastes
- Développe des traitements pour diverses affections, notamment la cicatrisation des plaies, la sclérose en plaques, la dégénérescence discale, le psoriasis, l’orthopédie et le cancer
- Détient un vaste portefeuille de brevets couvrant plusieurs domaines cliniques
FibroBiologics (Nasdaq: FBLG), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase mit über 240 Patenten, kündigte seine Teilnahme am ThymUS 2025 Meeting auf Hawaii an. Der Forschungswissenschaftler Simon Gebremeskel wird Ergebnisse zur Entwicklung künstlicher Thymus-Organoide zur Erzeugung funktionaler T-Zellen präsentieren.
Der Chief Scientific Officer des Unternehmens, Dr. Hamid Khoja, betonte das Potenzial künstlicher Thymus-Organoide, die Funktionalität des Thymus wiederherzustellen, der als Ausbildungszentrum für T-Zellen im Immunsystem dient. Die Forschung zeigt vielversprechende Anwendungen von Organoiden zur Behandlung chronischer Krankheiten unter Nutzung der einzigartigen immunmodulatorischen Eigenschaften von Fibroblasten.
Wichtige Unternehmenshighlights:
- Biotechnologieunternehmen in klinischer Phase mit Sitz in Houston
- Fokus auf Fibroblasten und fibroblastabgeleitete Materialien
- Entwicklung von Therapien für verschiedene Erkrankungen wie Wundheilung, Multiple Sklerose, Bandscheibendegeneration, Psoriasis, Orthopädie und Krebs
- Besitzt ein umfangreiches Patentportfolio in verschiedenen klinischen Bereichen
- Company holds 240+ US and international patents/patents pending across multiple therapeutic areas
- Diversified pipeline targeting major chronic diseases including MS, disc degeneration, psoriasis, and cancer
- Advancing research in artificial thymus organoid development with potential therapeutic applications
- Clinical-stage company with no marketed products yet
- Liquidity risks explicitly mentioned in forward-looking statements
- Capital resource constraints noted as a risk factor
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebremeskel, research scientist at FibroBiologics, is presenting a poster at the ThymUS 2025 Meeting taking place in Lihue, Kaua'i Hawaii from April 27 - May 1, 2025. Founded in 2001, ThymUS brings together international researchers working on thymus and T-cell biology.
The abstract entitled “A rapid and scalable thymus organoid development method for generating functional T cells” presents progress on the development of a transplantable and scalable artificial thymus organoid. The poster can be viewed on FibroBiologics’ website here.
“Our latest research demonstrates the potential of using an artificial thymus organoid to recover the lost functionality of the thymus, an organ that is the T-cell teaching center of the immune system,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “Organoids are transforming how we study and develop potential treatments for multiple chronic diseases. The unique immunomodulatory properties of fibroblasts offer promising potential in ensuring the functionality and durability of therapeutic organoids.”
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential and capabilities of fibroblasts and artificial thymus organoids to recover the lost functionality of the thymus. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business, and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is FibroBiologics (FBLG) presenting at ThymUS 2025 in Hawaii?
How many patents does FibroBiologics (FBLG) currently hold in 2025?
What is the potential impact of FibroBiologics' thymus organoid research?
When and where is the ThymUS 2025 Meeting featuring FBLG's research?
What clinical areas does FibroBiologics (FBLG) focus on in 2025?
